Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 14.20 is 522% above its 5-year average of 2.28, around the middle of its 5-year range (0.00–20.93).
As of the fiscal period ended Tuesday, June 30, 2026. 81.48% above its 12-month average of 7.82.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 14.20.
CURRENT RATIO
14.20
CURRENT RATIO AVG TTM
7.82
CURRENT RATIO AVG 3Y
1.88
CURRENT RATIO AVG 5Y
2.28
CURRENT RATIO AVG 10Y
N/A
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+81.48%
CURRENT VS 3Y AVG
+654.87%
CURRENT VS 5Y AVG
+522.02%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.35
median of 629 covered companies
CURRENT VS SECTOR MEDIAN
+323.78%
vs the sector median at left
Anteris Technologies Global Corp.
Market Cap
$689.86M
Current Ratio
14.20
TTM Avg
7.82
3Y Avg
1.88
5Y Avg
2.28
Market Cap
$688.75M
Current Ratio
19.69
TTM Avg
6.38
3Y Avg
9.16
5Y Avg
11.87
Market Cap
$697.00M
Current Ratio
8.86
TTM Avg
10.22
3Y Avg
11.35
5Y Avg
25.38
Market Cap
$705.76M
Current Ratio
1.03
TTM Avg
1.26
3Y Avg
1.17
5Y Avg
1.16
Market Cap
$721.69M
Current Ratio
0.95
TTM Avg
4.92
3Y Avg
2.98
5Y Avg
5.72
Market Cap
$722.25M
Current Ratio
19.31
TTM Avg
14.05
3Y Avg
7.67
5Y Avg
5.91
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anteris Technologies Global Corp. (AVR) | $689.86M | 14.20 | 7.82 | 1.88 | 2.28 |
| Faeth Therapeutics, Inc. (FTH)vs › | $688.75M | 19.69 | 6.38 | 9.16 | 11.87 |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $697.00M | 8.86 | 10.22 | 11.35 | 25.38 |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $705.76M | 1.03 | 1.26 | 1.17 | 1.16 |
| Annexon, Inc. (ANNX)vs › | $671.12M | 5.53 | 8.02 | 10.47 | 14.43 |
| MiMedx Group, Inc. (MDXG)vs › | $662.64M | 5.33 | 4.27 | 3.79 | 3.57 |
| Helus Pharma Inc. (HELP)vs › | $663.54M | 10.97 | 8.63 | 10.75 | 10.66 |
| Achieve Life Sciences, Inc. (ACHV)vs › | $721.69M | 0.95 | 4.92 | 2.98 | 5.72 |
| Avalo Therapeutics, Inc. (AVTX)vs › | $722.25M | 19.31 | 14.05 | 7.67 | 5.91 |
| Cytek Biosciences, Inc. (CTKB)vs › | $725.68M | 4.48 | 5.45 | 6.78 | 8.00 |
Current Ratio
14.20
Quick Ratio
14.20
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 14.20 |
| 2026-03-31 | 20.93 |
| 2025-12-31 | 0.73 |
| 2025-09-30 | 0.84 |
| 2025-06-30 | 2.41 |
| 2025-03-31 | 3.67 |
| 2024-12-31 | 4.51 |
| 2024-09-30 | 0.93 |
| 2024-06-30 | 0.91 |
| 2024-03-31 | 1.13 |
| 2023-12-31 | 2.56 |
| 2023-09-30 | 0.00 |
| 2023-06-30 | 2.98 |
| 2023-03-31 | 2.98 |
| 2022-12-31 | 2.40 |
| 2022-09-30 | 2.40 |
| 2022-06-30 | 4.31 |
| 2022-03-31 | 4.31 |
| 2021-12-31 | 2.00 |
| 2021-09-30 | 2.00 |
